Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) is expected to be issuing its Q2 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($1.40) per share and revenue of $0.65 million for the quarter. Parties can check the company’s upcoming Q2 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 3:30 PM ET.
Biorestorative Therapies Price Performance
BRTX opened at $1.48 on Wednesday. The company has a market cap of $2.04 million, a price-to-earnings ratio of -0.07 and a beta of 0.93. The firm has a 50 day simple moving average of $2.39 and a 200 day simple moving average of $6.25. Biorestorative Therapies has a fifty-two week low of $1.28 and a fifty-two week high of $30.17.
Analyst Ratings Changes
A number of equities analysts have issued reports on BRTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, August 24th. Maxim Group cut shares of Biorestorative Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Biorestorative Therapies presently has an average rating of “Reduce”.
View Our Latest Stock Analysis on Biorestorative Therapies
About Biorestorative Therapies
BioRestorative Therapies, Inc is a biotechnology company focused on developing regenerative medicine products using cell and tissue-based technologies. The company’s programs are intended to address conditions for which existing treatment options may be limited, including musculoskeletal and metabolic disorders.
Its lead product candidate, BRTX-100, is an autologous cell therapy developed from a patient’s own bone marrow and designed to treat painful lumbar disc disease, including chronic lower-back pain associated with degenerated discs.
Featured Articles
- Five stocks we like better than Biorestorative Therapies
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
